North America Immunodiagnostics Market Forecast to 2030
North America Immunodiagnostics Market Forecast to 2030 – Regional Analysis – by Product (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others), By Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)
$2,100 – $3,500
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Growing Use of Point-of-Care Immunodiagnostics Drive North America Industrial Robotics Market
Point-of-care testing (POCT) has become critical to patient-centric healthcare due to the need for rapid diagnostic results to determine accurate and faster treatments. A shift from centralized point-of-care testing to decentralized testing has resulted in easy access to these diagnostics. Immunoassay testing helps monitor chronic conditions and detect pathogens, such as bacteria and viruses. Advanced point-of-care devices enable rapid screening of up to three components from a single sample. Also, the point-of-care diagnostics (POCD) inclined toward mobile healthcare (mH) smart devices could revolutionize personalized healthcare monitoring and management, paving the way for next-generation POCTs. The management of infectious diseases can be significantly improved by POCTs, particularly in developing countries where access to timely medical care is challenging and healthcare infrastructure is outdated and sparse. Additionally, the technologically developed diagnostic kits leading to fewer manual errors propel the immunodiagnostics market. Several market players are developing innovative immunodiagnostics products. For instance, Thermo Fisher Scientific has developed immunodiagnostics products such as enzyme-linked immunoassay (ELISA) reagents and buffers, antibodies and detection probes, linking mechanisms, blocking buffers and detergents, detection substrates, and capture surfaces, as well as services such as bioconjugation and detection. Further, in September 2020, Roche launched the SARS-CoV-2 Rapid Antigen Test, which is used in POC settings to help healthcare professionals identify the infection within 15 minutes in people suspected of carrying the virus.
In April 2021, DiaSorin introduced the LIAISON IQ, a new immunodiagnostics Point-of-Care (POC) reader, and the LIAISON QuickDetect COVID TrimericS Ab test, developed with Lumos Diagnostics for countries accepting the CE Mark. Using a fingerstick of human capillary blood, this test for the LIAISON IQ identifies specific IgG antibodies against SARS-CoV-2 Spike Protein in 10 minutes.
In April 2021, Chembio Diagnostics, Inc. launched an FDA Emergency Use Authorization-approved, in-licensed rapid point-of-care COVID-19/Flu A&B test for use in traditional and decentralized testing settings. The rapid immunoassay test requires no instrumentation and produces results in 15 minutes.
WHO applauded the test kit developers for efforts taken to innovate and respond to the masses’ requirements during the COVID-19 crisis. According to the American Society for Clinical Pathology, in March 2020, the Cepheid Xpert Xpress SARS-CoV-2 test became the first POC COVID-19 detection assay to receive Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA).
Likewise, the use of immunodiagnostics in cancer treatment is increasing. In oncology, an immunodiagnostics test can confirm the presence of a solid tumor by detecting known tumor-associated antigens or antibodies. These advantages and indications are driving the immunodiagnostics market.
North America Immunodiagnostics Market Overview
The prevalence of cancer is increasing in the country at an alarming rate, leading to the rising demand for cancer diagnoses. According to the American Cancer Society’s (ASC) cancer facts & figures estimates for 2023, nearly 1.9 million new cancer cases were registered in the US. It is further projected that in 2023, the country will register 609,360 deaths from cancer, which is ~1,670 deaths a day. However, the increased diagnostics have reduced the number of cancer-linked deaths. As per the ASC, in the past 28 years, the death rate from cancer in men and women has fallen 32% from its peak in 1991 to 2019. The fall in death rates was found to be because of early and advanced cancer diagnoses. The awareness of the advancements in diagnostic technology has grown among people. Therefore, it has resulted in the significant growth of the immunoassay market in the US. Similarly, diabetes is prevailing at a high rate in the geriatric population in the US. Many companies are providing immunoassay kits for diabetes. For instance, Bio-Rad Laboratories, Inc. offers Bio-Plex Pro human diabetes immunoassays, which are reliable and convenient for studying human diabetes and obesity markers. They help in managing and treating diabetes in diabetic patients. The market is expected to witness significant growth due to the rising prevalence of diabetes among US citizens. According to the data published by the Centers for Disease Control and Prevention (CDC) in the 2023 National Diabetes Statistics Report, 37.3 million people have diabetes in the US, which accounts for 11.3% of the total US population. Also, the reports state that 96 million people aged 18 years or above are prediabetic, accounting for 38% of the US population. Thus, considering the prevalence of diabetes in the country, an increased demand for immunodiagnostics is anticipated, leading to market growth. There has been unprecedented growth in innovative and improved medical technologies in recent years. As a result, there have been developments in advanced diagnostics and the overall healthcare industry. Moreover, the US houses various companies developing cutting-edge products for point-of-care diagnosis, paving the way for the growth of the immunodiagnostics market. In April 2020, Bio-Rad Laboratories launched a blood-based immunoassay kit to identify antibodies to the SARS-CoV-2.
North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
North America Immunodiagnostics Market Segmentation
The North America immunodiagnostics market is segmented into product, clinical indication, end user, and country.
Based on product, the North America immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. In 2023, the enzyme-linked immunosorbent assays (ELISA) segment registered the largest share in the North America immunodiagnostics market. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.
Based on clinical indication, the North America immunodiagnostics market is segmented into infectious diseases, hepatitis+HIV, endocrinology, gastrointestinal, metabolics, and others. In 2023, the infectious diseases segment registered the largest share in the North America immunodiagnostics market. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.
Based on end user, the North America immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. In 2023, the hospitals segment registered the largest share in the North America immunodiagnostics market.
Based on country, the North America immunodiagnostics market is segmented into the US, Canada, Mexico. In 2023, the US registered the largest share in the North America immunodiagnostics market.
Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc are some of the leading companies operating in the North America immunodiagnostics market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Publishing status: | |
| Geographical coverage: | |
| Year of Publication: |
According to the research team Market research, the North America immunodiagnostics market was valued at US$ 10,463.48 million in 2023 and is expected to reach US$ 17,399.10 million by 2030, registering a CAGR of 7.5% from 2023 to 2030. Increasing prevalence of infectious diseases and growing use of point-of-care immunodiagnostics are the critical factors attributed to the North America immunodiagnostics market expansion.
The diagnosis and management of several ever-growing infectious diseases caused by infectious agents such as viruses, fungi, bacteria, parasites, or their toxic products are surging number of prescriptions for immunodiagnostics tests, e.g., complement fixation, precipitation tests, agglutination tests, line blot assays, Western blot assays, enzyme immunoassays (EIA), and immunofluorescence tests.
Human immunodeficiency virus (HIV) continues to be a major public health issue worldwide. In 2021, there were ~38.4 million people worldwide with HIV, as per the Joint United Nations Programme on HIV/AIDS (UNAIDS). Besides, hepatitis is another major factor driving the immunodiagnostics market. According to the World Health Organization (WHO), nearly 58 million people worldwide suffer from chronic hepatitis C infection, with 1.5 million new conditions occurring yearly. Furthermore, about 3.2 million adolescents and children have hepatitis C infection. Approved by all member states, the global hepatitis WHO strategy aims to reduce new hepatitis infections by 90% and mortalities by 65% during 2016–2030. Such global initiatives are fueling the demand for immunodiagnostics products.
Further, tuberculosis (TB), COVID-19, and other hospital-acquired infections (HAIs) require immunodiagnostics tests.
• TB has been the 13th leading cause of death and the second-leading infectious killer after COVID-19. In 2020, 1.5 million people died from TB and affected an estimated 10 million people, comprising 5.6 million males, 3.3 million females, and 1.1 million children globally.
• In 2021, a total of 7,860 TB cases were reported to CDC’s National Tuberculosis Surveillance System (NTSS) by the 50 states of America and the District of Columbia (DC).
• According to Worldometer, millions of deaths were reported worldwide due to the COVID-19 pandemic. It strained healthcare systems and increased the need for immunodiagnostics tests.
Diagnostics play a vital role in determining suitable medical treatments. Immunodiagnostics help diagnose diseases that severely impact the immune system. Hence, the rising prevalence of infectious diseases lead to the surging demand for immunodiagnostics products.
On the contrary, inadequate reimbursement scenario hurdles the growth of North America immunodiagnostics market.
Based on product, the North America immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. The enzyme-linked immunosorbent assays (ELISA) segment held 55.5% share of North America immunodiagnostics market in 2023, amassing US$ 5,812.20 million. It is projected to garner US$ 9,554.62 million by 2030 to expand at 7.4% CAGR during 2023–2030. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.
Based on clinical indication, the North America immunodiagnostics market is segmented into infectious diseases, hepatitis HIV, endocrinology, gastrointestinal, metabolics, and others. The infectious diseases segment held 44.4% share of North America immunodiagnostics market in 2023, amassing US$ 4,647.55 million. It is projected to garner US$ 8,021.81 million by 2030 to expand at 8.1% CAGR during 2023–2030. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.
Based on end user, the North America immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. The hospitals segment held 43.6% share of North America immunodiagnostics market in 2023, amassing US$ 4,561.04 million. It is projected to garner US$ 7,477.59 million by 2030 to expand at 7.3% CAGR during 2023–2030.
Based on country, the North America immunodiagnostics market is segmented into the US, Canada, Mexico. Our regional analysis states that the US captured 84.7% share of North America immunodiagnostics market in 2023. It was assessed at US$ 8,858.38 million in 2023 and is likely to hit US$ 14,596.10 million by 2030, exhibiting a CAGR of 7.4% during 2023–2030.
Key players operating in the North America immunodiagnostics market are Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc, among others.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America immunodiagnostics market.
o Highlights key business priorities in order to assist companies to realign their business strategies
o The key findings and recommendations highlight crucial progressive industry trends in the North America immunodiagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the immunodiagnostics market, as well as those hindering it
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Research Team Report Guidance
1.3 Market Segmentation
1.3.1 North America Immunodiagnostics Market – by Product
1.3.2 North America Immunodiagnostics Market – by Clinical Indication
1.3.3 North America Immunodiagnostics Market – by End User
1.3.4 North America Immunodiagnostics Market – by Country
2. North America Immunodiagnostics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Immunodiagnostics Market – Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Expert’s Opinion
5. North America Immunodiagnostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Infectious Diseases
5.1.2 Growing Use of Point-of-Care Immunodiagnostics
5.2 Market Restraints
5.2.1 Inadequate Reimbursement Scenario
5.3 Market Opportunities
5.3.1 Rising Focus on R&D Investment and Expansion by Key Players
5.4 Future Trends
5.4.1 Technological Advancements in Immunodiagnostics
5.5 Impact Analysis
6. Immunodiagnostics Market – North America Analysis
6.1 North America Immunodiagnostics Market Revenue Forecast and Analysis
7. North America Immunodiagnostics Market Analysis – by Product
7.1 Overview
7.2 North America Immunodiagnostics Market, By Product, 2022 & 2030 (%)
7.3 Enzyme-linked Immunosorbent Assays (ELISA)
7.3.1 Overview
7.3.2 Enzyme-linked Immunosorbent Assays (ELISA): North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4 Chemiluminescence Immunoassays (CLIA)
7.4.1 Overview
7.4.2 Chemiluminescence Immunoassays (CLIA): North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.3 Vitamin D Assay
7.4.3.1 Overview
7.4.3.2 Vitamin D Assay: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.4 HIV Detection
7.4.4.1 Overview
7.4.4.2 HIV Detection: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.5 HIV Ag/Ab Combo assay
7.4.5.1 Overview
7.4.5.2 HIV Ag/Ab Combo Assay: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.6 Other Tests
7.4.6.1 Overview
7.4.6.2 Other Tests: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.5 Radioimmunoassays (RIA)
7.5.1 Overview
7.5.2 Radioimmunoassays (RIA): North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8. North America Immunodiagnostics Market Analysis – Clinical Indication
8.1 Overview
8.2 North America Immunodiagnostics Market Share by Clinical Indication – 2022 & 2030 (%)
8.3 Infectious Diseases:
8.3.1 Overview
8.3.2 Infectious Diseases: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.1 COVID-19
8.3.2.1.1 Overview
8.3.2.1.2 COVID-19: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.2 Tuberculosis
8.3.2.2.1 Overview
8.3.2.2.2 Tuberculosis: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.3 Lyme
8.3.2.3.1 Overview
8.3.2.3.2 Lyme: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.4 Infection Management
8.3.2.4.1 Overview
8.3.2.4.2 Infection Management: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.5 Zika
8.3.2.5.1 Overview
8.3.2.5.2 Zika: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.6 Treponema
8.3.2.6.1 Overview
8.3.2.6.2 Treponema: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.7 TORCH
8.3.2.7.1 Overview
8.3.2.7.2 TORCH: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.8 Measles and Mumps
8.3.2.8.1 Overview
8.3.2.8.2 Measles and Mumps: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.9 VZV
8.3.2.9.1 Overview
8.3.2.9.2 VZV: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.10 EBV
8.3.2.10.1 Overview
8.3.2.10.2 EBV: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.4 Hepatitis+HIV:
8.4.1 Overview
8.4.2 Hepatitis+HIV: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.5 Gastrointestinal
8.5.1 Overview
8.5.2 Gastrointestinal: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.6 Metabolic Disorders
8.6.1 Overview
8.6.2 Metabolics: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7 Endocrinology
8.7.1 Overview
8.7.2 Endocrinology: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.3 Hypertension
8.7.3.1 Overview
8.7.3.2 Hypertension: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.4 Growth
8.7.4.1 Overview
8.7.4.2 Growth: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.5 Diabetes
8.7.5.1 Overview
8.7.5.2 Diabetes: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.6 Thyroid
8.7.6.1 Overview
8.7.6.2 Thyroid: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.7 Reproductive Endocrinology
8.7.7.1 Overview
8.7.7.2 Reproductive Endocrinology: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9. North America Immunodiagnostics Market Analysis – End User
9.1 Overview
9.2 North America Immunodiagnostics Market Share by End User – 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.5 Diagnostic Laboratories
9.5.1 Overview
9.5.2 Diagnostic Laboratories: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.6 Academic and Research Institutes
9.6.1 Overview
9.6.2 Academic and Research Institutes: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
10. North America Immunodiagnostics Market – Revenue and Forecast to 2030 – Country Analysis
10.1 Overview
10.1.1.1 US: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 US: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.3 US: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.1.3.1 US: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.4 US: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.4.1 US: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.4.2 US: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.5 US: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.1.2 Canada: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Canada: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.3 Canada: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.2.3.1 Canada: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.4 Canada: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.4.1 Canada: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.4.2 Canada: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.5 Canada: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.1.3 Mexico: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 Mexico: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.3 Mexico: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.3.3.1 Mexico: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.4 Mexico: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.4.1 Mexico: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.4.2 Mexico: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.5 Mexico: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
11. North America Immunodiagnostics Market –Industry Landscape
11.1 Overview
11.2 Inorganic Growth Strategies
11.2.1 Overview
11.3 Organic Growth Strategies
11.3.1 Overview
12. Company Profiles
12.1 Abbott Laboratories
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 F. Hoffmann-La Roche Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 DiaSorin SpA
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Danaher Corp
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Thermo Fisher Scientific Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 PerkinElmer Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 bioMerieux SA
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Svar Life Science AB
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Siemens Healthcare GmbH
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. US Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 2. US Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 3. US Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 4. US Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 5. US Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 6. US Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 7. Canada Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 8. Canada Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 13. Mexico Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 19. Recent Inorganic Growth Strategies in the Immunodiagnostics Market
Table 20. Recent Organic Growth Strategies in the Immunodiagnostics Market
Table 21. Glossary of Terms, North America Immunodiagnostics Market
LIST OF FIGURES
Figure 1. North America Immunodiagnostics Market Segmentation
Figure 2. North America Immunodiagnostics Market, by Country
Figure 3. North America Immunodiagnostics Market Overview
Figure 4. Enzyme-Linked Immunosorbent Assays (ELISA) Segment Held Largest Share of Product Segment in North America Immunodiagnostics Market
Figure 5. Canada Expected to Show Remarkable Growth During Forecast Period
Figure 6. North America: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. North America Immunodiagnostics Market: Impact Analysis of Drivers and Restraints
Figure 9. North America Immunodiagnostics Market – Revenue Forecast and Analysis – 2021–2030
Figure 10. North America Immunodiagnostics Market, by Product, 2022 & 2030 (%)
Figure 11. Enzyme-linked Immunosorbent Assays (ELISA): North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 12. Chemiluminescence Immunoassays (CLIA): North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 13. Vitamin D Assay: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 14. HIV Detection: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 15. HIV Ag/Ab Combo Assay: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 16. Other Tests: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 17. Radioimmunoassays (RIA): North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 18. Others: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 19. North America Immunodiagnostics Market Share by Clinical Indication – 2022 & 2030 (%)
Figure 20. Infectious Diseases: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 21. COVID-19: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 22. Tuberculosis: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 23. Lyme: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 24. Infection Management: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 25. Zika: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 26. Treponema: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 27. TORCH: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 28. Measles and Mumps: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 29. VZV: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 30. EBV: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 31. Hepatitis+HIV: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 32. Gastrointestinal: North America Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 33. Metabolics: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 34. Endocrinology: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 35. Hypertension: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 36. Growth: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 37. Diabetes: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 38. Thyroid: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 39. Reproductive Endocrinology: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 40. Endocrinology: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 41. North America Immunodiagnostics Market Share by End User – 2022 & 2030 (%)
Figure 42. Hospitals: North America Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 43. Clinics: North America Immunodiagnostics Market Revenue and Forecasts To 2030 (US$ Million)
Figure 44. Diagnostic Laboratories: North America Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 45. Academic and Research Institutes: North America Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 46. Others: North America Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 47. North America: Immunodiagnostics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 48. North America: Immunodiagnostics Market, by Country, 2022 & 2030 (%)
Figure 49. US: Immunodiagnostics market – Revenue and Forecast to 2030 (US$ Million)
Figure 50. Canada: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 51. Mexico: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
The List of Companies – North America Immunodiagnostics Market
o Abbott Laboratories
o bioMerieux SA
o Danaher Corp
o DiaSorin SpA
o F. Hoffmann-La Roche Ltd
o PerkinElmer Inc
o Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
o Siemens Healthcare GmbH
o Svar Life Science AB
o Thermo Fisher Scientific Inc
You must be logged in to post a review.
Reviews
There are no reviews yet.